Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

NCT01401959 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

127

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Eribulin
DRUG: Trastuzumab

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]